Mountain View, United States
NeuroPace, headquartered in the United States, has been pioneering solutions in the health care and medical devices industry since its founding in 1999. The company's flagship product, the RNS System, is the first and only brain-responsive neurostimulation device targeting refractory focal epilepsy, a condition affecting approximately 1% of the global population.
Distinct from other technologies, the NeuroPace RNS System is akin to a pacemaker for the brain, continuously monitoring and responding to neurological activity. This breakthrough technology not only addresses epilepsy but also holds potential for treating other debilitating neurological disorders, enhancing quality of life for millions worldwide.
Backed by a $9.30M grant investment from the National Institutes of Health as of June 30, 2021, NeuroPace remains a promising player in its field, opening avenues for further innovations in neurostimulation therapies.
